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Despite the fact that betablockers (BBs) are one 
of the main groups of therapy of patients with acute 
myocardial infarction (AMI), the comparative 
effectiveness of various BBs in patients with 
postinfarction cardiosclerosis (PICS) is uncertain. 
There was performed comparative analysis of clinical 
efficacy of BBs in patients with chronic heart failure 
(CHF) on the background of coronary heart disease 
(CHD), PICS. There was evaluated the impact of 
metoprolol succinate, carvedilol, bisoprolol and 
betaxolol on blood pressure (BP), left ventricular 
ejection fraction (LVEF), change the functional class 
of chronic heart failure, and mortality in patients over 
4 years. It is established that the BBs therapyblood 
pressure decreased equally, without significant 
differences between the groups (р˃0,05). There was a 
positive effect on the increase of the LVEF all the 
BBs (p<0.01), bisoprolol was exerted more 
pronounced effect (p<0.01). Comparative assessment 
of BBseffectiveness showed that the reducti0on of 
the functional class of chronic heart failure was in the 
bisoprolol treatment by 43.7% (p<0.001), carvedilol 
by 32.3% (p<0.001), betaxolol by 27.3% (p<0.01) 
and metoprolol succinate by 25.6% (p<0.01). 
Differences between groups were significant in favor 
of bisoprolol. Also, our study investigated the 
influence of BB streatment on the mortality of 
patients with CHD, PICS, which was performedby 
year for 4 years. Depending on the duration of 
observation for 1year mortality was 7.4% for 2 years 
it was 11.6%, for 3 years it was 10.5%, for 4 year it 
was 24.3% (p<0.01 in all cases in comparison with 
the group without BBs administration). The reduction 
in mortality associated with treatment with beta 
blockers during the year was 27.5%, 2 years – 34.8%, 
3 years – 67.2% and 4 years 35.9%. Thus, the 
administration of betablockers can significantly 
reduce mortality in patients with postinfarction 
cardiosclerosis, starting from the first year of 
treatment. And this positive effect persists and 
accumulates in the future. 
Key words: chronic heart failure, drug therapy, 
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Introduction 
The concept of beta-adrenergic 
receptorsblockade as a therapeutic method for 
chronic heart failure (CHF) was developed by the 
Gothenburg group (Sweden) in the seventies [1, 2]. 
In subsequent experiments on larger selections with a 
placebo-controlled clinical trials there was confirmed 
the efficiency of the beta-adrenergic receptors 
blockade in the treatment of heart failure [3]. Then 
there were begun a series of studies that to date have 
presented convincing evidence for the efficacy of 
betablockers (BBs) as a therapeutic agent in heart 
failure [4, 5]. 
However, some questions of the mechanisms of 
development [6, 7] and progression of CHF in 
patients after myocardial infarction [8], as well as the 
medical administration of the BBs in this category of 
patients remain controversial. These include, first, the 
rationality of itsadministration in patients with 
postinfarction cardiosclerosis (PICS) at the stage of 
rehabilitation treatment due to a negative inotropic 
action on the myocardium. Also further evaluation of 
their effects on the left ventricular systolic [9] and 
diastolic dysfunction [10, 11], special aspects the 
actions of BBS on quality of life [12, 13], as well as 
the individual characteristics of the action of 
betablockers and their influence on mortality [14, 15] 
of patients is neсessary. 
In clinical practice, due to a cautious attitude of 
physicians towards the BBS modern and more 
effective drugs in this group are administrated less 
frequently than it’s required. Existing varieties of 
beta blockers represent non-selectivedrugs, such as 
propranolol, timolol, and selective beta-1blockers, 
such as metoprolol, atenolol, bisoprolol and
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 betaxolol. An example of the next generation of 
BBSare drugs with vasodilatory and metabolic 
activity, its mechanisms of actions are varied, such as 
carvedilol with vasodilatory property and nebivolol 
with a pronounced antioxidant activity [16]. 
Clinical efficacy of BBS in patients with CHF 
was studied in several placebo controlled trials. 
Significance and efficiency of the BBSin CHF can be 
confirm the results of a sufficiently long (not less 
than 3 months) randomized clinical trials (RCTs). It 
should be recalled that the results of only three large 
and well-organized RCTs (MERIT-HF – Metoprolol 
CR/XL Randomized Intervention Trial in Congestive 
Heart Failure, CIBIS II – Cardiac Insufficiency 
Bisoprolol Study and COPERNICUS – Carvedilol 
Prospective Randomized Cumulative Survival) to 
evaluate the application of the BBS (metoprolol 
succinate, bisoprolol and carvedilol) in comparison 
with placebo showed a decrease in mortality about 
35% [17]; also there is a unit comparison of the 
effectiveness of non-selective BBS carvedilol and the 
most commonly administrated beta-1selective BBS 
(bisoprolol, metoprolol and nebivolol) in patients 
with acute myocardial infarction (AMI) after 
percutaneous cardiac catheter intervention (PCI) [18] 
which not found differences impact on all-cause 
mortality and AMI. 
Today the question of optimal BBS therapy in 
patients with ischemic CHFis not studied, as it 
requires a direct comparison of drugs in RCTS. This, 
in turn, determines the importance of studying the 
influence of BBS on mortality in patients with CHF 
as a result of the outcome of myocardial infarction, 
what is the purpose of the present study. 
Materials and methods 
The clinical efficacy of the BBS in our study 
was studied in 168 patients. All patients suffered 
from myocardial infarction within the deadline more 
than 6 months before the examination. The patients 
with acute symptoms of heart failure, unstable 
patients with CHF and acute forms of coronary heart 
disease (CHD) were rejected from the study. 
Essential hypertension was detected in 100% (168) of 
patients, and its duration was 10.2 ± 1.5 years (from 4 
to 16 years). 
Systolic function of the left ventricle was 
determined by the left ventricular ejection fraction 
(LVEF) index. The average LVEF index of the 
patients was 43 ± 0.8%. To determine the functional 
class of CHF used the classification of New York 
Heart Association (NYHA). The average FC of CHF 
according to rating NYNA was 2.8 ± 0.06. BBS were 
administrated in the complex standard of 
pharmacotherapy of CHF: angiotensin-converting 
enzyme inhibitors / angiotensin receptor blockers, 
diuretics, and cardiac glycosides (digoxin) if it’s 
91ecessary. The metoprolol succinate, betaxolol, 
bisoprolol, and carvedilol were administrated of the 
BBS. The duration of the treatment ranged from 12 
months to 4 years. 
In a group of 168 patients, where there was the 
analysis of the effectiveness of the BBS treatment 
within one year, metoprolol succinate was 
administrated to 56 (33.3%) patients, carvedilol – to 
35 (20.8%), bisoprolol to 43 (25.6%) and betaxolol to 
34 (20.3%). Males were 110 (65.5%) and females 
were 58 (34.5%). The age of patients according to 
gender and groups, taking BBS, did not differ 
significantly and averaged (63.0 ± 6.0). Impact on 
mortality was performed annually throughout the 
period of supervision. 
Statistical processing of the obtained data was 
carried out on a personal computer by methods of 
variation statistics using the software packages 
“Microsoft Excel”, “Statistica” using the student’s t 
test. The data are presented in the form (M±m). 
Differences were considered significant at p < 0.05. 
Main part 
Baseline blood pressure (ABP), systolic (SBP) 
and diastolic (DBP) were almost identical in all 
patients (table 1). 
Table 1 
Dynamics of ABP level in the BBS therapy(M±m) 
Drug 
Number 
 of subjects, 
n 
ABP level, mm Hg 
Baseline ABP ABP after 12 months 
SBP DBP SBP DBP 
Metoprolol succinate 56 174 ± 3.8 99 ± 4.0 146 ± 2.1 76 ± 3.1 
Carvedilol 35 176 ± 9.9 97 ± 5.6 137 ± 4.7 75 ± 2.9 
Bisoprolol 43 172 ± 8.0 98 ± 4.8 135 ± 5.2 78 ± 3.4 
Betaxolol 34 168 ± 6.4 98 ± 4.2 131 ± 2.8 78 ± 3.3 
 
Significant differences between the groups were 
not found. However, hypotensive effect and blood 
pressure reduction are most significantly manifested 
in patients treated with carvedilol (Figure 1). 
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Figure 1. Pharmacodynamic effects of BBS in patients with CHF on the background of coronary heart disease (CHD), 
postinfarction cardiosclerosis (PICS) * – р˂0,05 in comparison with baseline group 
 
There was performed the assessment of BBS on 
the systolic function of the left ventricle of the heart. 
It is established that under the influence of the BBS 
treatment there was an increase in ejection fraction 
(Figure 2) to varying degrees. 
 
Figure 2. Pharmacodynamic effects of BBS in patients with CHF on the background of coronary heart disease (CHD), 
postinfarction cardiosclerosis (PICS). Change the LVEF in the course of the BBS treatment 
 
Patients treated with metoprolol succinate, the 
baseline EF was 42.4 ± 1.8%, and in the course of the 
treatment it increased to 48.6 ± 1.8% or by 14.6% 
(p<0.05). In the group of patients treated with 
carvedilol, the baseline EFwas 41.6 ± 1.9%. After 
treatment it was 48.1 ± 2.1%, or increased by 15.7% 
(p<0.05). In patients group treated with bisoprolol 
dynamics of EF ranged from 42.6 ± 1.8% to 48.8 ± 
1.8% or increased by 16.5% (p<0.01). Treatment with 
betaxolol has also led to an increase of the EF index 
from 42.6 ± 1.8% to 48.8 ± 1.8% or by 14.6% (p<0.05).  
Consequently, bisoprolol had a more 
pronounced positive effect on the increase in the EF 
in patients with chronic cardiac insufficiency on the 
background of ischemic heart disease, postinfarction 
cardiosclerosis. Other betablockers: metoprolol 
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succinate, carvedilol, and betaxolol improve ejection 
fraction in a less degree. A statistically significant 
difference between the groups were not found. 
Analysis of the impact of BBS on the course of 
CHF showed that the average changes of the 
functional class of CHF in the entire group of patients 
treated with betablockers, has changed from 3.0 ± 
0.05 units to 2.0 ± 0.04 units (p<0.001), by 1.0 units 
(33.3%) (p<0.01) (table 3). In the group treated with 
metoprolol succinate overall average of the 
functional class of CHF in the course of the treatment 
has changed from 2.9 ± 0.05 to 2,1 ± 0.03 units 
(p<0.001) by 0.8 units (27.6%). Carvedilol therapy 
(35 patients) led to decrease of the functional class of 
CHF in all patients. The baseline functional class of 
CHF corresponded to 3.1 ± 0.05 units with a 
significant decrease to 2.1 ± 0.04 units (p<0.001),by 
1.0 units (32.3%). Bisoprolol was treated 43 patients 
with coronary heart disease, postinfarction 
cardiosclerosis. The baseline overall average of the 
functional class of CHFin this group was 3.2 ± 0.06 
units, and in response to treatment decreased to 1.8 ± 
0.05 units, by 1.4 units (43.7%) (p<0.001). The 
baseline overall average offunctional class of CHF in 
betaxolol group was 3.0 ± 0.05 units, after treatment 
it decreased by 0.8 units (25%) to 2.2 ± 0,04 units 
(p<0.01). 
Table 3 
Changes in functional class of chronic heart failure in patients with CHD, PICS after 12 months  
of therapy with beta blockers (M±m) 
Drug 
Number of subjects, 
n 
The functional class of CHF 
р 
Before treatment After treatment 
Metoprolol succinate 56 2.9 ± 0.05 2.1 ± 0.03 <0.01 
Carvedilol 35 3.1 ± 0.05 2.1 ± 0.04 <0.001 
Bisoprolol 43 3.2 ± 0.06 1.8 ± 0.05 <0.001 
Betaxolol 34 3.0 ± 0.05 2.2 ± 0.04 <0.01 
All: 168 3.0 ± 0.05 2.0 ± 0.04 <0.001 
 
Comparative evaluation of the effectiveness of 
BBS have shown that the decrease of the functional 
class of CHF was in group of bisoprolol 43.7% 
(p<0.001), carvedilol – 32.3% (p<0.001), betaxolol – 
27.3% (p<0.01) and metoprolol succinate – 25.6% 
(p<0.01). Differences between groups were 
significant in favor of bisoprolol.  
Also in our study we investigated the influence 
of treatment of BBS on the mortality of patients with 
CHD, PICS, which was arranged by the years within 
4 years (table 4). 
Table 4 
Comparative analysis of the influence of BBS therapy on mortality of patients with postinfarction 
cardiosclerosis 
Patient categories 
Characteristics of patients by years of supervision 
All 
2012 2013 2014 2015 
All 80 90 85 84 339 
1. Without BBS treatment, n 49 43 38 39 169 











2. BBS therapy, n 32 47 44 45 168 























During the 4 years there were supervised 339 
patients, of which in 2012 – 80 2013 – 90, 2014 – 85, 
2015 – 84 patients. Of the 339 patients with 
postinfarction cardiosclerosis 168 patients (49.6%) were 
treated with betablockers. BBS therapy in 2012 was 
prescribedto 40% of patients, 2013 to 52.2%, 2014 to 
56.8% and 2015 to 53.6%. Analyzing the mortality of 
patients with postinfarction cardiosclerosis depending 
on the administration of the betablockers we should say 
that the total number of patients died in the group 
treated with BBS was 21 and the general mortality was 
12.5%. Among the patients was not treatedwith 
betablockersthere were 43 died, which accounted for 
25.4% of the 171 patients (p<0.01 in comparison with 
the treatment group). In theBBS treatment depending on 
the duration of supervision of 1 year mortality was 
7.4% for 2 years it was 11.6%, for 3 years it was 10.5%, 
for 4 years it was 24.3% (p<0.01 in all cases in 
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comparison with the group without the administration 
of BBS). The decrease of the mortality associated with 
BBS treatment during the year was 27.5%, 2 years it 
was 34.8%, 3 years it was 67.2% and 4 years it was 
35.9%. 
Comparative evaluation of the effect of the BBS 
on mortality in patients depending on the drug showed 
that in the group of patients treated by metoprolol 
succinate 8 patients were died, which accounted for 
14.3% of the number of patients taking the drug. In the 
group taking carvedilol the number of died patients was 
4 (11.4 %), bisoprololum it was 3 (6.9%) and betaxolol 
it was 6 patients (17.6%) (table 5). 
Table 5 
Comparative evaluation of the effect of the BBS on mortality of patients with CHD, PICS depending on BBS 
Drug 
Statistical values 
n (М, %) male/female Age, М ± m Mortality 
Metoprolol succinate 56 (62.5%) 35/21 65.8 ± 4 8 (14.3%) 
Carvedilol 35 (60%) 21/14 63.2 ± 7 4 (11.4%) 
Bisoprolol 43 (53.5%) 28/15 62.4 ± 7 3 (6.9%) 
Betaxolol 34 (76.5%) 26/8 62.1 ± 5 6 (17.6%) 
All 168 (65.5%) 110/58 63.0 ± 6 21 (12.5%) 
 
Results and evaluation 
RCTs are the gold standard for delivering the 
foundations of therapy. Post hoc analyses, systematic 
reviews, and meta-analyses are post marketing tools 
that help refine or make sense of the collective 
evidence. All the small and large RCTs using BBs in 
CHF have answered the question of safety and 
efficacy very well. Studies have set out to enroll 
cohorts with a good spectrum of illness severity, as 
detailed in the NYHA class and mean LVEF. To 
control for confounders, studies may have controlled 
the heterogeneity of the other demographic and 
comorbid variables. Why is this important? 
Guidelines are shaped around the findings of large 
RCTs, and appear to suggest that findings from these 
homogeneous studies apply equally to heterogeneous 
«real-world» patients. This may, in fact, be the case, 
although examples are presenting that a broader 
perspective may be needed. Female sex and race have 
not received good representation in any RCT. Post 
hoc analysis from MERIT-HF and pooling of results 
with CIBIS II and COPERNICUS show similar 
survival in women and men [19, 20].  
BBs therapy is not enough administrated for 
CHF and diabetes, and complications of diabetes, 
such as nephropathy, partly because of the historical 
problems of tolerability, adverse hemodynamic and 
metabolic effects, and lack of selectivity of the BBs. 
Heterogeneity within the class of BBs, perhaps, is the 
biggest problem in its prescription. It can be argued 
that BBs with vasodilatory properties, such as 
carvedilol and nebivolol theoretically may have 
advantages in improving metabolic profile and 
kidney function, as they reduce insulin resistance and 
not adversely impact on the blood glucose level [21, 
22]. Also the question remains about the optimal dose 
of BBs at CHF. The results of the study of BBs as 
antiarrhythmic drugs are also scarce and 
conflicting.A rhythm-based strategy in atrial 
fibrillation and HF is less clear. The main 
pharmacological therapies that are used in 
maintaining sinus rhythm are either contraindicated 
as with flecainide, not proven with sotalol, or have 
long-term toxicity concerns with amiodarone. 
Between 10% and 35% of trial participants have 
comorbid atrial fibrillation, whereby the most recent 
10-study meta-analysis could not demonstrate an 
outcome benefit with BBs [23].  
The main goal of therapy in patients with 
coronary heart disease, postinfarction cardiosclerosis 
is improve long-term outcomes, that is the secondary 
prevention of this disease [2, 3, 24]. In our study, 
bisoprolol was the drug with the highest degree of a 
positive effect on decrease of the severity and course 
of chronic heart failure, and then the carvedilol and 
betaxolol. To a lesser extent, but quite noticeable this 
effect is observed in metoprolol succinate. Also the 
study of the influence of the BBs on the mortality of 
patients with CHF on the back of CHD after 
myocardial infarction showed the reduction of 
mortality for 4 years by 35.9%. Comparative 
evaluation of the effect of the beta-blockers on 
mortality in patients depending on the drug showed 
that in the group of patients treated by metoprolol 
succinate 8 patients were died, which accounted for 
14.3% of the number of patients taking the drug. In 
the group taking carvedilol it was 4 (11.4%), 
bisoprolol it was 3 (6.9%) and betaxolol 6 patients 
(17.6%). Thus, the beta-blockers therapy can 
significantly reduce of mortality in patients with 
postinfarction cardiosclerosis, starting from the first 
year of treatment. And this positive effect persists 
and accumulates in the future. 
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Conclusion 
Summing up set out on the effects of beta-
blockers on the severity of CHF in patients with 
postinfarction cardiosclerosis, it can be argued that 
bisoprolol has the most positive impact on reducing 
of CHF, and then the carvedilol and betaxolol. To a 
lesser extent, but quite noticeable this effect is 
observed in metoprolol. Thus, the beta-blockers 
therapy can significantly reduce of mortality in 
patients with postinfarction cardiosclerosis, starting 
from the first year of treatment. And this positive 
effect persists and accumulates in the future. 
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